IOVA vs MRK
Iovance Biotherapeutics, Inc. vs Merck & Co. — AI-powered side-by-side comparison
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
VS
| Metric | IOVA | MRK |
|---|
| AI Score |
67
|
70
|
| Price |
$6.49
|
$130.34
|
| P/E Ratio |
-9.27×
|
103.53×
|
| ROE |
-56.0%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
116.3%
|
75.4%
|
| Debt / Equity |
0.06×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
79.2
|
64.5
|
| Beta |
0.701
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for IOVA versus MRK.
MRK leads by 3 points.
MRK scores 70/100 (Buy) versus IOVA at 67/100 (Buy).
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical